| scholarly article | Q13442814 |
| P2093 | author name string | Yujin Hoshida | |
| Nicolas Goossens | |||
| Rosa S Kim | |||
| P2860 | cites work | An integrated encyclopedia of DNA elements in the human genome | Q22122150 |
| The accessible chromatin landscape of the human genome | Q24595581 | ||
| Enabling transparent and collaborative computational analysis of 12 tumor types within The Cancer Genome Atlas | Q24595911 | ||
| Predicting new molecular targets for known drugs | Q24649687 | ||
| Predicted exposures to steroid estrogens in U.K. rivers correlate with widespread sexual disruption in wild fish populations | Q24683218 | ||
| Cryo electron microscopy to determine the structure of macromolecular complexes | Q26774271 | ||
| Crowdsourcing for bioinformatics | Q27025464 | ||
| Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer | Q27851410 | ||
| A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response | Q27851728 | ||
| Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. | Q27852316 | ||
| Improved overall survival in melanoma with combined dabrafenib and trametinib | Q27853091 | ||
| First-line crizotinib versus chemotherapy in ALK-positive lung cancer | Q27853101 | ||
| Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer | Q27853134 | ||
| Integrative clinical genomics of advanced prostate cancer | Q27853170 | ||
| Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas | Q27853175 | ||
| Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. | Q27853298 | ||
| Learning the parts of objects by non-negative matrix factorization | Q28146173 | ||
| The Connectivity Map: a new tool for biomedical research | Q28530408 | ||
| A survey of current trends in computational drug repositioning | Q28602324 | ||
| TP Atlas: integration and dissemination of advances in Targeted Proteins Research Program (TPRP)—structural biology project phase II in Japan | Q28728538 | ||
| Landscape of transcription in human cells | Q29547467 | ||
| The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease | Q29547614 | ||
| The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity | Q29547693 | ||
| Systematic identification of genomic markers of drug sensitivity in cancer cells | Q29547695 | ||
| Personal omics profiling reveals dynamic molecular and medical phenotypes | Q29614800 | ||
| Drug target identification using side-effect similarity | Q29615103 | ||
| The long-range interaction landscape of gene promoters | Q29615403 | ||
| A new initiative on precision medicine | Q29615654 | ||
| Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia | Q29615735 | ||
| Nivolumab and ipilimumab versus ipilimumab in untreated melanoma | Q29620657 | ||
| Structure-based inhibition of protein-protein interactions. | Q30367145 | ||
| A comprehensive review of the lipid cubic phase or in meso method for crystallizing membrane and soluble proteins and complexes. | Q30371030 | ||
| In silico methods to predict drug toxicity | Q30432339 | ||
| Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease | Q30526431 | ||
| Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation | Q33349703 | ||
| Phynx: an open source software solution supporting data management and web-based patient-level data review for drug safety studies in the general practice research database and other health care databases | Q33506455 | ||
| In silico tools for sharing data and knowledge on toxicity and metabolism: derek for windows, meteor, and vitic | Q33519656 | ||
| Counterpoint: Data first | Q33548637 | ||
| Disruption of ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptor by cancer-associated missense mutations | Q52536030 | ||
| Genomics-enabled drug repositioning and repurposing: insights from an IOM Roundtable activity | Q53540508 | ||
| Origin of the resistance of leukaemic cells to folic acid antagonists. | Q54747803 | ||
| Lung cancer: a new generation of EGFR inhibition. | Q55059413 | ||
| Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine | Q63199223 | ||
| Effects of combinations of antileukemic agents on an acute lymphocytic leukemia of mice | Q73021418 | ||
| Big data in biomedicine | Q74209431 | ||
| Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation | Q75447880 | ||
| Altered ligand binding by insulin-like growth factor II/mannose 6-phosphate receptors bearing missense mutations in human cancers | Q78257341 | ||
| NCI-MATCH launch highlights new trial design in precision-medicine era | Q85528297 | ||
| The ENCODE project | Q85826761 | ||
| GSK collaborates with Apple on ResearchKit | Q86419188 | ||
| Trends in risks associated with new drug development: success rates for investigational drugs | Q34096792 | ||
| Detecting novel associations in large data sets | Q34102548 | ||
| Using physiologically-based pharmacokinetic-guided "body-on-a-chip" systems to predict mammalian response to drug and chemical exposure | Q34143269 | ||
| Diversity-oriented synthesis-facilitated medicinal chemistry: toward the development of novel antimalarial agents | Q34394236 | ||
| Clinical development success rates for investigational drugs | Q34396786 | ||
| An integrated map of structural variation in 2,504 human genomes | Q34496621 | ||
| The ToxCast program for prioritizing toxicity testing of environmental chemicals | Q34564990 | ||
| ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time | Q35033300 | ||
| A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity. | Q35201777 | ||
| Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints | Q35226583 | ||
| Genetic and proteomic approaches to identify cancer drug targets | Q35683353 | ||
| Metagene projection for cross-platform, cross-species characterization of global transcriptional states | Q35719918 | ||
| Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor. | Q35745721 | ||
| Key factors in the rising cost of new drug discovery and development | Q35770173 | ||
| Cancer biomarker discovery and validation | Q35879887 | ||
| Large-scale prediction and testing of drug activity on side-effect targets | Q36059863 | ||
| Clinical trial designs incorporating predictive biomarkers. | Q36534713 | ||
| Defining principles of combination drug mechanisms of action | Q36535401 | ||
| Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy | Q36586426 | ||
| Identification of type 2 diabetes subgroups through topological analysis of patient similarity | Q36659399 | ||
| In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling | Q36840592 | ||
| A review of modern multiple hypothesis testing, with particular attention to the false discovery proportion. | Q36910192 | ||
| The productivity crisis in pharmaceutical R&D. | Q37883027 | ||
| Direct to consumer genetic testing: a systematic review of position statements, policies and recommendations. | Q37988920 | ||
| High-throughput methods for combinatorial drug discovery | Q38148743 | ||
| Predicting drug metabolism: experiment and/or computation? | Q38439385 | ||
| Machine learning applications in genetics and genomics | Q38463061 | ||
| An ecosystem of cancer cell line factories to support a cancer dependency map. | Q38863819 | ||
| Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators | Q40225712 | ||
| Pharmaceuticals in the environment: scientific evidence of risks and its regulation | Q42075651 | ||
| Methods for Building QSARs | Q43438203 | ||
| Dilute Concentrations of a Psychiatric Drug Alter Behavior of Fish from Natural Populations | Q44455089 | ||
| Personalized medicine: Time for one-person trials | Q46268988 | ||
| Imprinted M6p/Igf2 receptor is mutated in rat liver tumors | Q47886657 | ||
| Optimal two-stage enrichment design correcting for biomarker misclassification | Q50764565 | ||
| Predicting multiple ecotoxicological profiles in agrochemical fungicides: a multi-species chemoinformatic approach | Q51565098 | ||
| QSAR modeling of toxicity of diverse organic chemicals to Daphnia magna using 2D and 3D descriptors. | Q51760484 | ||
| An evaluation of the implementation of the Cramer classification scheme in the Toxtree software | Q52227990 | ||
| P433 | issue | 3 | |
| P921 | main subject | big data | Q858810 |
| P304 | page(s) | 245-253 | |
| P577 | publication date | 2016-04-28 | |
| P1433 | published in | Expert review of precision medicine and drug development | Q27727536 |
| P1476 | title | Use of big data in drug development for precision medicine | |
| P478 | volume | 1 |
| Q48595289 | Cell type-specific pharmacological kinase inhibition for cancer chemoprevention. |
| Q36229691 | Macromolecular target prediction by self-organizing feature maps |
| Q62496001 | Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery |
| Q90402943 | Relationships Between a History of Abuse, Changes in Body Mass Index, Physical Health, and Self-Reported Depression in Female Bariatric Surgery Patients |
| Q92702195 | Technical Blossom in Medical Care: The Influence of Big Data Platform on Medical Innovation |
| Q91727289 | Use of big data in drug development for precision medicine: an update |
Search more.